Novadip Biosciences: Funding, Investors & Team (Oct 2026)
A biopharmaceutical business called Novadip Biosciences was established with the goal of creating, developing, and commercializing cutting-edge stem cell-based treatments for regenerative medicine. A completely unique and 3D osteogenic scaffold-free structure makes up Novadip Biosciences' first proprietary cellular therapy, which offers cutting-edge treatments for severe bone healing diseases. In order to create 3D natural bone implants with the required shape, mineralization, and mechanical qualities for replacement and healing of significant bone defects, their primary product, NVD-001, presents new principles of guided tissue regeneration based on stem cells from adipose tissue. To further his ground-breaking cell therapy pipeline, NOVADIP raised a EUR 28 million Series A Round with US and Belgian investors in September 2015.
Novadip Biosciences has raised $35.3M across 2 funding rounds on record, the most recent a Convertible Note of $11.9M announced in Sep 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Novadip Biosciences Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Novadip Biosciences Funding Rounds
Novadip Biosciences raised $23.4M in a Series B announced in Nov 2022.
3.8 years later, a Convertible Note of $11.9M was announced in Sep 2026.
Novadip Biosciences Investors
17 investors are recorded in total; the 5 named above are those the record identifies.
Novadip Biosciences Founders and Leadership Team
Contact details for the Novadip Biosciences team: 2 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Novadip Biosciences Funding Compared to Other Biotechnology Startups
Novadip Biosciences' latest round of $11.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Novadip Biosciences in Biotechnology and Mont-saint-guibert
Companies Similar to Novadip Biosciences
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
Novadip Biosciences Funding FAQs
What does Novadip Biosciences do?
A biopharmaceutical business called Novadip Biosciences was established with the goal of creating, developing, and commercializing cutting-edge stem cell-based treatments for regenerative medicine. A completely unique and 3D osteogenic scaffold-free structure makes up Novadip Biosciences' first proprietary cellular therapy, which offers cutting-edge treatments for severe bone healing diseases. In order to create 3D natural bone implants with the required shape, mineralization, and mechanical qualities for replacement and healing of significant bone defects, their primary product, NVD-001, presents new principles of guided tissue regeneration based on stem cells from adipose tissue. To further his ground-breaking cell therapy pipeline, NOVADIP raised a EUR 28 million Series A Round with US and Belgian investors in September 2015.
How much funding has Novadip Biosciences raised?
Novadip Biosciences has raised $35.3M across 2 rounds on record. The most recent is a Convertible Note of $11.9M announced in Sep 2026.
When did Novadip Biosciences last raise funding?
Novadip Biosciences' most recent funding round on record is a Convertible Note of $11.9M, announced in Sep 2026.
Who has invested in Novadip Biosciences?
Investors on record for Novadip Biosciences include New Science Ventures, Vives Louvain Technology Fund, WE International, Sambrinvest, Noshaq. FundedIQ records 17 investors in total.
Who founded Novadip Biosciences?
FundedIQ lists Denis Dufrane (CEO & Scientific Founder) at Novadip Biosciences.
Where is Novadip Biosciences headquartered?
Novadip Biosciences is based in Mont-saint-guibert, Brabant Wallon, Belgium.
How many employees does Novadip Biosciences have?
Novadip Biosciences is in the 11-50 employee band.
When was Novadip Biosciences founded?
Novadip Biosciences was founded in 2013.
How does Novadip Biosciences' funding compare to other Biotechnology startups?
Novadip Biosciences' latest round of $11.9M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Novadip Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Novadip Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.